Logo image of PCRX

PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD

25.16  -0.58 (-2.25%)

After market: 25.3 +0.14 (+0.56%)

Fundamental Rating

6

Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 193 industry peers in the Pharmaceuticals industry. PCRX has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on PCRX. These ratings could make PCRX a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
In the past 5 years PCRX always reported a positive cash flow from operatings.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

1.2 Ratios

PCRX has a better Return On Assets (-5.37%) than 76.22% of its industry peers.
PCRX has a Return On Equity of -10.91%. This is in the better half of the industry: PCRX outperforms 76.22% of its industry peers.
With an excellent Return On Invested Capital value of 6.55%, PCRX belongs to the best of the industry, outperforming 85.41% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 44.06%.
The last Return On Invested Capital (6.55%) for PCRX is above the 3 year average (4.32%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -5.37%
ROE -10.91%
ROIC 6.55%
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

1.3 Margins

PCRX's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 13.59%, PCRX belongs to the top of the industry, outperforming 84.32% of the companies in the same industry.
PCRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 73.82%, PCRX is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 13.59%
PM (TTM) N/A
GM 73.82%
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
PCRX has more shares outstanding than it did 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
PCRX has a better debt/assets ratio than last year.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 1.82 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.82, PCRX is in the better half of the industry, outperforming 65.95% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 3.04, which is a good value as it means it would take PCRX, 3.04 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.04, PCRX belongs to the top of the industry, outperforming 90.81% of the companies in the same industry.
A Debt/Equity ratio of 0.51 indicates that PCRX is somewhat dependend on debt financing.
PCRX has a worse Debt to Equity ratio (0.51) than 64.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF 3.04
Altman-Z 1.82
ROIC/WACC0.75
WACC8.76%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.25 indicates that PCRX has no problem at all paying its short term obligations.
With a Current ratio value of 2.25, PCRX perfoms like the industry average, outperforming 43.24% of the companies in the same industry.
A Quick Ratio of 1.89 indicates that PCRX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.89, PCRX perfoms like the industry average, outperforming 42.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 1.89
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

PCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.72%, which is quite good.
PCRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.93% yearly.
The Revenue has grown by 29.50% in the past year. This is a very strong growth!
The Revenue has been growing by 14.88% on average over the past years. This is quite good.
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%

3.2 Future

Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.86% on average per year.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.03% on average per year.
EPS Next Y9.62%
EPS Next 2Y9.67%
EPS Next 3Y13.25%
EPS Next 5Y13.86%
Revenue Next Year3.26%
Revenue Next 2Y4.44%
Revenue Next 3Y5.41%
Revenue Next 5Y6.03%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.89 indicates a rather cheap valuation of PCRX.
Based on the Price/Earnings ratio, PCRX is valued cheaper than 94.59% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.62, PCRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.16, the valuation of PCRX can be described as very cheap.
PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 92.97% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, PCRX is valued rather cheaply.
Industry RankSector Rank
PE 7.89
Fwd PE 7.16
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 95.68% of the companies in the same industry.
PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 96.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6
EV/EBITDA 5.63
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PCRX's earnings are expected to grow with 13.25% in the coming years.
PEG (NY)0.82
PEG (5Y)0.34
EPS Next 2Y9.67%
EPS Next 3Y13.25%

More info and screens

0

5. Dividend

5.1 Amount

PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/21/2025, 8:00:00 PM)

After market: 25.3 +0.14 (+0.56%)

25.16

-0.58 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners112.14%
Inst Owner Change-97.53%
Ins Owners2.41%
Ins Owner Change35.19%
Market Cap1.16B
Analysts74.29
Price Target27.69 (10.06%)
Short Float %11.55%
Short Ratio5.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.37%
Min EPS beat(2)9.93%
Max EPS beat(2)24.81%
EPS beat(4)2
Avg EPS beat(4)7.73%
Min EPS beat(4)-2.59%
Max EPS beat(4)24.81%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)4
Avg EPS beat(12)-6.49%
EPS beat(16)7
Avg EPS beat(16)-5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-2.6%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.05%
Min Revenue beat(4)-2.6%
Max Revenue beat(4)1.18%
Revenue beat(8)1
Avg Revenue beat(8)-2.41%
Revenue beat(12)1
Avg Revenue beat(12)-2.3%
Revenue beat(16)2
Avg Revenue beat(16)-2.21%
PT rev (1m)49.75%
PT rev (3m)41.79%
EPS NQ rev (1m)5.19%
EPS NQ rev (3m)5.19%
EPS NY rev (1m)1.41%
EPS NY rev (3m)3.89%
Revenue NQ rev (1m)1.53%
Revenue NQ rev (3m)1.53%
Revenue NY rev (1m)0.39%
Revenue NY rev (3m)0.92%
Valuation
Industry RankSector Rank
PE 7.89
Fwd PE 7.16
P/S 1.35
P/FCF 6
P/OCF 5.7
P/B 1.55
P/tB 3.76
EV/EBITDA 5.63
EPS(TTM)3.19
EY12.68%
EPS(NY)3.51
Fwd EY13.96%
FCF(TTM)4.19
FCFY16.66%
OCF(TTM)4.41
OCFY17.54%
SpS18.67
BVpS16.24
TBVpS6.7
PEG (NY)0.82
PEG (5Y)0.34
Profitability
Industry RankSector Rank
ROA -5.37%
ROE -10.91%
ROCE 9.64%
ROIC 6.55%
ROICexc 10.46%
ROICexgc 24.8%
OM 13.59%
PM (TTM) N/A
GM 73.82%
FCFM 22.45%
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
ROICexc(3y)6.29%
ROICexc(5y)6.55%
ROICexgc(3y)29.94%
ROICexgc(5y)22.81%
ROCE(3y)6.36%
ROCE(5y)5.99%
ROICexcg growth 3Y-7.41%
ROICexcg growth 5Y10.67%
ROICexc growth 3Y-15.58%
ROICexc growth 5Y0.45%
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF 3.04
Debt/EBITDA 2
Cap/Depr 13.52%
Cap/Sales 1.19%
Interest Coverage 9.06
Cash Conversion 105.52%
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 1.89
Altman-Z 1.82
F-Score6
WACC8.76%
ROIC/WACC0.75
Cap/Depr(3y)71.34%
Cap/Depr(5y)91.2%
Cap/Sales(3y)5.08%
Cap/Sales(5y)5.29%
Profit Quality(3y)415.67%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
EPS Next Y9.62%
EPS Next 2Y9.67%
EPS Next 3Y13.25%
EPS Next 5Y13.86%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%
Revenue Next Year3.26%
Revenue Next 2Y4.44%
Revenue Next 3Y5.41%
Revenue Next 5Y6.03%
EBIT growth 1Y73.26%
EBIT growth 3Y13.01%
EBIT growth 5Y37.92%
EBIT Next Year22.34%
EBIT Next 3Y18.38%
EBIT Next 5Y16.96%
FCF growth 1Y108.99%
FCF growth 3Y52.67%
FCF growth 5Y32.31%
OCF growth 1Y61.24%
OCF growth 3Y26.17%
OCF growth 5Y25.89%